The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC).
 
Biagio Ricciuti
No Relationships to Disclose
 
Christine Champagne
No Relationships to Disclose
 
Greg Jones
Employment - Inivata
Patents, Royalties, Other Intellectual Property - Patent for plasma cfDNA sequencing and prediction of I/O therapy response (Inst)
 
Tadd Scott Lazarus
Employment - Clinical Genomics
Consulting or Advisory Role - Inivata
 
Anika E. Adeni
No Relationships to Disclose
 
Michael L. Cheng
Honoraria - Lynx Group; Potomac Center for Medical Education; WebMD
Consulting or Advisory Role - AstraZeneca; Inivata
Travel, Accommodations, Expenses - Allergan; AstraZeneca; Daiichi Sankyo; Guardant Health; Natera; Potomac Center for Medical Education; Sanofi; WebMD
 
Geoffrey R. Oxnard
Honoraria - Foundation Medicine; Guardant Health; Sysmex
Consulting or Advisory Role - Abbvie; AstraZeneca; DropWorks; GRAIL; Illumina; Inivata; Janssen; LOXO; Merck; Merck; Sysmex; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)